TrialESMO open2022

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).

W Okamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.